Commentary
Alcohol-related liver disease is associated with significant changes in gut microbial composition. Treatment approaches on the gut microbiota, such as diet, probiotics, antibiotics and faecal microbial transplantation can restore intestinal homeostasis and improve alcohol-related liver disease (1).
Dysbiosis of the intestinal microbiota has been associated with NAFLD. In this randomized trial of patients with NAFLD by E. Scorletti et al., administration of a symbiotic combination (probiotic and prebiotic) altered faecal microbiomes but did not reduce liver fat content or markers of liver fibrosis (2).
1. Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol 2019;70:260-272.
2. Scorletti E, Afolabi PR, Miles EA, et al. Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease. Gastroenterology 2020.
